Zura Bio Limited (ZURA)
| Bid | 1.63 |
| Market Cap | 102.4M |
| Revenue (ttm) | 2K |
| Net Income (ttm) | -64.44M |
| EPS (ttm) | -0.77 |
| PE Ratio (ttm) | -2.15 |
| Forward PE | -1.8 |
| Analyst | Buy |
| Ask | 1.74 |
| Volume | 462,593 |
| Avg. Volume (20D) | 749,243 |
| Open | 1.73 |
| Previous Close | 1.72 |
| Day's Range | 1.64 - 1.75 |
| 52-Week Range | 0.97 - 5.07 |
| Beta | -0.06 |
About ZURA
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for ZURA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
4 weeks ago · businesswire.com
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway anti...
2 months ago · https://www.defenseworld.net
Squarepoint Ops LLC Cuts Stock Position in Zura Bio Limited (NASDAQ:ZURA)Squarepoint Ops LLC lessened its stake in Zura Bio Limited (NASDAQ:ZURA – Free Report) by 48.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange C...
2 months ago · businesswire.com
Zura Bio to Present at the Jefferies Global Healthcare ConferenceHENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway anti...
2 months ago · businesswire.com
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaHENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio launches TibuSHIELD, a Phase 2 study evaluating tibulizumab in adults with hidradenitis suppurativa.